Sign inJoin waitlistJoin the waitlist

Brandon Mancini

Clinical Assistant Professor, Department of Medicine · Western Michigan University Homer Stryker MD School of Medicine

Credentials: · · · · ·

History

Western Michigan University Homer Stryker MD School of Medicine
Present

MBA 2016, Healthcare Administration, School of Management, Yale University
2015–2016
Radiation Oncology
Yale-New Haven Hospital
2011–2015
MBA 2016, Healthcare Administration, School of Management, Yale University
2011–2012
MBA 2016, Healthcare Administration, School of Management, Yale University
Wayne State University School of Medicine
2007–2011
University of Michigan
2003–2007

Research

Results of the 2013-2015 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States
International journal of radiation oncology · 2016 · 79 citations
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology · 2015 · 73 citations
Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base
Cancer · 2015 · 56 citations

Charles Rutter
11 papers · 10 as a resident
Henry Park
11 papers · 11 as a resident
Christopher Corso
8 papers · 8 as a resident
Debra Yeboa
7 papers · 7 as a resident
Nataniel Lester-Coll
7 papers · 6 as a resident
RD
Roy Decker
7 papers
EH
Eileen Harder
5 papers · 5 as a resident
Cary Gross
4 papers
James Hayman
4 papers
James Yu
4 papers
SJ
Shruti Jolly
4 papers
Daniel Spratt
3 papers

Clinical trials

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Site PI · Recruiting · Phase 1
Novartis Pharmaceuticals
2024–2031
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2031
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Site PI · Recruiting · Phase 1, Phase 2
Perspective Therapeutics
2023–2029
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Site PI · Recruiting · Phase 1, Phase 2
Clarity Pharmaceuticals Ltd
2021–2026